BioStem Technologies Inc. (OTCMKTS:BSEM) Stock Continues to Trend Higher: Here is Why
The regenerative medicine space has evolved at a fairly decent clip over the course of the past few years, and currently, it is one of the more attractive niches for investors. There are some companies in the sector that could be worth looking into, and in light of developments from yesterday, it could well be BioStem Technologies Inc. (OTCMKTS:BSEM).
The company is a leading player in that space and is involved in the manufacturing, development, and commercialization of biologics derived from placentas for the purpose of providing highly advanced wound care. Yesterday, the company entered the news cycle after it announced that it had entered into an agreement with Venture Medical LLC, a leading player in the United States wound care solutions market.
Through this agreement, the company’s innovative wound care product, AminoWrap2, would be distributed by Venture Medical. The company announced in its news release that the product in question was an advanced biologic substitute for skin, which it had processed with meticulousness. The product would offer a wide range of wound care and wound healing solutions. The Chief Executive Officer and Chairman of BioStem Technologies, Jason Matuszewski, spoke about the development as well.
He noted that the commercial launch of AminoWrap2 was a significant new milestone for the company as it continued to expand its offerings in the wound care space. He went on to state that everyone at the company was pleased at the fact that, through its commercial partner Venture Medical, the product would reach patients and healthcare providers across the United States. Matuszewski also stated that the product was the latest addition to BioStem Technologies’ line-up of products and had been created through the deployment of the proprietary BioREtain process. The proprietary process helped with the creation of an allograft, which originated from amniotic tissue. Hence, it could also be used in a range of wound care applications.
On September 18, the company was also in the news after it announced that it had hired the services of PCG Advisory Inc. to provide advisory services to BioStem Technologies pertaining to strategic communications and investor relations. PCG Advisory is a digital strategy firm and a leader in the investor relations space. The company revealed that PCG Advisory would work with the senior management at the company to further strengthen its investor relations outreach.
It would create a shareholder communications initiative that would be designed to boost the visibility of the company across the investment community. Matuszewski spoke about the development at the time as well. He noted that everyone at BioStem Technologies was delighted at the possibility of working in collaboration with PCG Advisory at a time when the company was looking to further boost its manufacturing capacity. He went on to note that one of the major goals of the company for 2023 was to provide extra value to both the shareholders and clients. The latest move would help the company boost investor awareness, he asserted.
